

CEO Hanna Sjöström invited as panelist at Stanford Impact1 CEO Summit in Austin, Texas

Neola Medical announces that CEO Hanna Sjöström will participate in the Stanford Impact1 CEO Summit on Pediatric and Maternal Health Innovation for the third consecutive year. The summit, hosted in Austin, Texas, September 18-19, 2025, convenes leading MedTech entrepreneurs, investors, pediatric experts, and representatives from the U.S. Food and Drug Administration (FDA) to accelerate innovations that can transform pediatric and maternal healthcare.

This year, CEO Hanna Sjöström has been invited as a panelist in “Managing Board and Investor Relationships”, a session highlighting how leadership can successfully navigate strategic partnerships, governance, and capital markets to advance breakthrough healthcare technologies.

“It is an honor to return to the Stanford Impact1 CEO Summit and to contribute to the important dialogue around board and investor relationships. As a Stanford Impact1 company, Neola Medical benefits greatly from the expertise and networks that this unique program provides. The exclusive CEO Summit is an invaluable forum to share our journey, connect with thought-leaders, and exchange perspectives on how to bring impactful innovations like Neola® to pediatric patients worldwide,” says CEO Hanna Sjöström.

Neola Medical was selected in 2023 as a Stanford Impact1 company, recognized for its pioneering work with Neola® (Neonatal Lung Analyzer). The program was founded to accelerate innovations that can make a difference from day one in the clinic and provides unique support from Stanford University’s experts in neonatology, medical technology, and commercialization.

Read the press release about the Stanford Impact1 program announcement 2023 here: https://www.neolamedical.com/mfn_news/stanford-utser-neola-medicals-medicintekniska-produkt-till-en-viktig-innovation-for-neonatalvarden-och-ger-bolaget-stod-till-marknadsetablering-genom-exklusiva-programmet-impact1/

Watch the welcome speech to the Stanford Impact1 program in 2023 by founding director, [James Wall](#), here: <https://www.linkedin.com/feed/update/urn:li:activity:7119952940315926529>

About Stanford Impact1

Stanford Impact1 was founded to address the urgent need for pediatric and maternal health innovations. Each year, far fewer medical technologies are approved for children than for adults, leaving pediatric specialists without the advanced tools required for their most vulnerable patients. Impact1 leverages Stanford Biodesign’s need-driven innovation process and provides access to world-leading clinicians, engineers, and Silicon Valley experts in product development, regulation, intellectual property, reimbursement, and commercialization. Learn more here: <https://biodesign.stanford.edu/programs/impact1.html>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com**About Neola Medical**

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments[Stanford Impact1 CEO Summit 2025](#)**Attachments**[CEO Hanna Sjöström invited as panelist at Stanford Impact1 CEO Summit in Austin, Texas](#)